非小细胞肺癌EGFR-TKI耐药机制及治疗的研究进展  

Research progress of resistance mechanism and overcoming strategies of EGFR-TKI in non-small cell lung cancer

作　　者：刘欣怡 郭子涵 蒋云秀 左安力 鲁德玕[1] Liu Xinyi;Guo Zihan;Jiang Yunxiu;Zuo Anli;Lu Degan(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Shandong Institute of Respiratory Diseases,Shandong Institute of Anesthesia and Respiratory Critical Medicine,Jinan 250014,China)

机构地区：[1]山东第一医科大学第一附属医院(山东省千佛山医院)呼吸与危重症医学科、山东省呼吸疾病研究所、山东省麻醉与呼吸危重症研究所,济南250014

出　　处：《国际呼吸杂志》2023年第7期759-765,共7页International Journal of Respiration

基　　金：山东省自然科学基金(ZR2021LSW015);济南市呼吸疾病临床医学研究中心项目(202132002)。

摘　　要：肺癌是全球发病率和病死率均位居前列的一种肿瘤,严重危害人类健康。其中,非小细胞肺癌(NSCLC)患者占80%~85%。表皮生长因子受体(EGFR)突变是NSCLC中最常见的基因突变类型之一,也是NSCLC治疗的重要靶点。表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)是EGFR敏感突变NSCLC患者的一线选择,然而,耐药不可避免。本文对NSCLC患者EGFR-TKI耐药机制及耐药后治疗的研究进展进行阐述。Lung cancer is one of the most common malignancies with the highest incidence and mortality worldwide,which seriously endangers human health.Non-small cell lung cancer(NSCLC)accounts for 80%to 85%of all lung cancer patients.Epidermal growth factor receptor(EGFR)mutation is one of the most frequent genetic abnormalities in NSCLC,and is also an important target for NSCLC therapy.Epithelial growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)is the first-line treatment choice for NSCLC patients with EGFR-sensitive mutations.However,drug resistance is inevitable.This article reviews the research progress on the resistance mechanism and treatment strategies of EGFR-TKI in NSCLC.

关 键 词：癌 非小细胞肺 基因 erbB-1 表皮生长因子受体 酪氨酸激酶抑制剂 耐药性 

分 类 号：R734.2[医药卫生—肿瘤]